Voss Capital, Lp Buys 178,392 Shares of Rein Therapeutics (NASDAQ:RNTX) Stock

Rein Therapeutics Inc. (NASDAQ:RNTX) major shareholder Voss Capital, Lp bought 178,392 shares of the company’s stock in a transaction on Tuesday, October 28th. The shares were bought at an average cost of $1.39 per share, for a total transaction of $247,964.88. Following the transaction, the insider owned 500,000 shares in the company, valued at $695,000. The trade was a 55.47% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Voss Capital, Lp also recently made the following trade(s):

• On Monday, October 27th, Voss Capital, Lp bought 97,482 shares of Rein Therapeutics stock. The shares were bought at an average cost of $1.37 per share, for a total transaction of $133,550.34.
• On Friday, October 24th, Voss Capital, Lp bought 30,176 shares of Rein Therapeutics stock. The shares were bought at an average cost of $1.39 per share, for a total transaction of $41,944.64.

Rein Therapeutics Trading Up 17.4%

NASDAQ:RNTX opened at $1.55 on Thursday. The company has a market cap of $36.13 million, a PE ratio of -0.58 and a beta of 1.14. Rein Therapeutics Inc. has a twelve month low of $1.04 and a twelve month high of $4.16. The company’s 50 day moving average is $1.25 and its two-hundred day moving average is $1.50.

Rein Therapeutics (NASDAQ:RNTX) last released its earnings results on Thursday, August 14th. The company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.06). As a group, analysts expect that Rein Therapeutics Inc. will post -1.56 EPS for the current fiscal year.

Institutional Trading of Rein Therapeutics

Several large investors have recently made changes to their positions in RNTX. Blair William & Co. IL purchased a new stake in shares of Rein Therapeutics in the 2nd quarter valued at $33,000. Chicago Partners Investment Group LLC acquired a new position in shares of Rein Therapeutics in the 2nd quarter valued at $64,000. Exencial Wealth Advisors LLC acquired a new position in shares of Rein Therapeutics in the 2nd quarter valued at $43,000. University of Texas Texas AM Investment Management Co. acquired a new position in shares of Rein Therapeutics in the 2nd quarter valued at $716,000. Finally, Sigma Planning Corp acquired a new position in shares of Rein Therapeutics in the 2nd quarter valued at $387,000. 90.89% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

RNTX has been the topic of several research analyst reports. HC Wainwright initiated coverage on shares of Rein Therapeutics in a research report on Monday, September 22nd. They set a “buy” rating and a $10.00 target price on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Rein Therapeutics in a report on Wednesday, October 8th. Finally, Brookline Capital Management downgraded shares of Rein Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, August 19th. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $10.00.

About Rein Therapeutics

Rein Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers.